Feasibility planning study of lattice radiotherapy for palliation in bulky tumors

Abstract

Purpose: Lattice radiotherapy can potentially deliver high doses to the tumor core, while conventional doses to the periphery resulting in improved response rates in large tumors (> 5 cm).We assessed the feasibility of planning lattice radiotherapy and dosimetrically compared it with conventional radiotherapy.

Methods: This retrospective dosimetric study evaluated 10 patients with large tumors (>5 cm) treated with palliative intent with a dose of 20Gy in five fractions. High-dose lattice pointswere created at doses of 50Gy in non-hepatic tumors and 35Gy in hepatic tumors. Lattice plans were compared with treatment plans regarding dose coverage and organ-at-risk dosimetry.

Results: Treated sites included soft tissue metastases to the neck, lungs, abdomen, pelvis, and liver. The mean lesion volume was 1103 cc (352–3173 cc). The maximum tumor size was 16 cm. The target volume coverage was > 95% in all but one case (88% to achieve organ constraints). Dosimetry and organ-at-risk doses were similar in both palliative treatment and simulated lattice plans.

Conclusion: Lattice radiotherapy is feasible in large tumors using volumetricmodulated arc therapy and achieves good coverage while meeting organ constraints. However, a prospective clinical evaluation is required to confirm its efficacy.

Keywords

dosimetry / Lattice radiotherapy / palliative radiotherapy

References

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 73(1):17-48.

[2] van Oorschot B, Rades D, Schulze W, Beckmann G, Feyer P. Palliative radiotherapy—new approaches. Semin Oncol. 2011;38(3):443-449.

[3] Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: An ASTROevidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965-976.

[4] Spencer K, Parrish R, Barton R, Henry A. Palliative radiotherapy. BMJ. 2018;k821.

[5] Ferini G, Parisi S, Lillo S, et al. Impressive results after “Metabolism-Guided” lattice irradiation in patients submitted to palliative radiation therapy: Preliminary results of LATTICE_01multicenter study. Cancers (Basel). 2022;14(16):3909.

[6] Fukunaga H, Butterworth KT, McMahon SJ, Prise KM. Abrief overview of the preclinical and clinical radiobiology ofmicrobeam radiotherapy. Clin Oncol. 2021;33(11):705-712.

[7] Wu X, Perez NC, Zheng Y, et al. The technical and clinical implementation of LATTICE Radiation Therapy (LRT). Radiat Res. 2020;194(6):737-746.

[8] Ferini G, Valenti V, Tripoli A, et al. Lattice or oxygen-guided radiotherapy: What if they converge? Possible future directions in the Era of immunotherapy. Cancers (Basel). 2021;13(13):3290.

[9] Alanizy NA, Attalla EM, Abdelaal AM, Yassen MN, Shafaa MW. Biological evaluation of Grid versus 3D Conformal Radiotherapy in bulky head and neck cancer. JMed Phys. 2022;47(2):136-140.

[10] Amendola BE, Perez NC, Wu X, Blanco Suarez JM, Lu JJ, Amendola M. Improved outcome of treating locally advanced lung cancer with the use of Lattice Radiotherapy (LRT): A case report. Clin Transl Radiat Oncol. 2018;9:68-71.

[11] Amendola BE, Perez NC, Mayr NA, Wu X, Amendola M. Spatially fractionated radiation therapy using lattice radiation in far-advanced bulky cervical cancer: A clinical and molecular imaging and outcome study. Radiat Res. 2020;194(6):724-736.

[12] Amendola BE, Perez NC, Wu X, Amendola MA, Qureshi IZ. Safety and efficacy of Lattice radiotherapy in voluminous non-small cell lung cancer. Cureus. 2019;11(3):e4263.

[13] At B, Velayudham R. Assessing dosimetric advancements in spatially fractionated radiotherapy: From grids to lattices. Med Dosim. 2024;49(3):206-214.

[14] Wang F, Ong ALK. Lattice radiotherapy: where less is more? Ann Palliat Med. 2022;11(12):3587-3591.

[15] Duriseti S, Kavanaugh JA, Szymanski J, et al. LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. Radiother Oncol. 2022;167:317-322.

[16] Zhang H, Wu X, Zhang X, et al. Photon GRID radiation therapy: A physics and dosimetrywhite paper from the radiosurgery society (RSS) GRID/LATTICE, microbeam and FLASH radiotherapy working group. Radiat Res. 2020;194(6):665-677.

[17] Duriseti S, Kavanaugh J, Goddu S, et al. Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors. Adv Radiat Oncol. 2021;6(3):100639.

[18] Diez P, Hanna GG, Aitken KL, et al. UK 2022 Consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin Oncol. 2022;34(5):288-300.

[19] Pellizzon ACA. Lattice radiation therapy-its concept and impact in the immunomodulation cancer treatment era. Rev Assoc Med Bras. 2020;66(6):728-731.

[20] Kanagavelu S, Gupta S, Wu X, et al. In Vivo effects of lattice radiation therapy on local and distant lung cancer: Potential role of immunomodulation. Radiat Res. 2014;182(2):149-162.

[21] Tubin S, Khan MK, Salerno G, Mourad WF, Yan W, Jeremic B. Monoinstitutional phase 2 study of innovative Stereotactic Body Radio-Therapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound nontargeted effects by sparing peri-tumoral immune microenvironment. Radiat Oncol. 2019;14(1):212.

[22] Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patientswith advanced non–small cell lung cancer. JAMA Oncol. 2019;5(9):1276.

[23] Ferini G, Castorina P, Valenti V, et al. A novel radiotherapeutic approach to treat bulky metastases even from cutaneous squamous cell carcinoma: Its rationale and a look at the reliability of the linearquadratic model to explain its radiobiological effects. Front Oncol. 2022;12:809279.

[24] Wu X, Ahmed MM, Wright J, Gupta S, Pollack A. On modern technical approaches of three-dimensional high-dose lattice radiotherapy (LRT). Cureus. 2010;2(3):e9.

[25] Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: An ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12(1):28-51.

[26] Pennock M, Klein J, Lock M. Palliative radiotherapy for hepatic tumors: a narrative review of indications and recommendations. Ann Palliat Med. 2023;12(6):1420-1446.

[27] Bang A, Dawson LA. Radiotherapy for HCC: Ready for prime time? JHEP Rep. 2019;1(2):131-137.

[28] Ohri N, Tomé WA, Méndez Romero A, et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys. 2021;110(1):188-195.

[29] Yan W, Khan MK, Wu X, et al. Spatially fractionated radiation therapy: History, present and the future. Clin Transl Radiat Oncol. 2020;20:30-38.

[30] Yuan K, Liao X, Yao X, et al. Study on lattice radiotherapy treatments (LRT) for Head and Neck Bulky Tumors. Int J Radiat Oncol Biol Phys. 2023;117(2):e596-e597.

RIGHTS & PERMISSIONS

2024 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

AI Summary ^{中 Eng} ×

Note: Please be aware that the following content is generated by artificial intelligence. This website is not responsible for any consequences arising from the use of this content.

AI Summary AI Mindmap

×

Share on WeChat

Part of a collection:

125

Accesses

0

Citation

Altmetric

Detail

Sections

Recommended

[31] Ertan F, Yeginer M, Zorlu F. Dosimetric performance evaluation of MLC-based and cone-based 3D spatially fractionated LATTICE radiotherapy. Radiat Res. 2023;199(2):161-169.